chinfloxacin

Chinfloxacin (also known as chinfloxacin hydrochloride or IMB-031124) is a novel synthetic tricyclic fluoroquinolone antibiotic. It was jointly developed by the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences and Zhejiang Medicine. Structurally, chinfloxacin is an analog of moxifloxacin, featuring a difluoride substitution in the 8-methoxy group, which imparts improved pharmacological properties and safety margins. Chinfloxacin acts by inhibiting bacterial DNA gyrase and DNA topoisomerase IV, thereby disrupting bacterial DNA replication and transcription. It exhibits potent, concentration-dependent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative pathogens, including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. Chinfloxacin has been evaluated in Phase 1 clinical trials in China for the treatment of conventional and biothreat bacterial infections, demonstrating favorable safety, tolerability, and pharmacokinetic profiles.

Other names

chinfloxacin hydrochloride